{"id":"W3184251505","doi":"10.1016/j.cllc.2021.07.002","title":"Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Medicine; Ipilimumab; Internal medicine; Tolerability; Lung cancer; Adverse effect; Oncology; Population; Common Terminology Criteria for Adverse Events; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002655257,0.001067843,0.00174763,0.0003023135,0.000264724,0.0008378014,0.0007585594,0.0009425455,0.002293096],"category_scores_gemma":[0.001009919,0.0003470393,0.001182367,0.0003823131,0.0006330521,0.0005808023,0.0002803791,0.002997073,0.0005774568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007374177,"about_ca_system_score_gemma":0.001096243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003607938,"about_ca_topic_score_gemma":0.000984308,"domain_scores_codex":[0.9994594,0.0002657996,0.0000434377,0.00009211437,0.00006645115,0.00007265792],"domain_scores_gemma":[0.9989399,0.0002049484,0.0002956299,0.0000726557,0.00007131438,0.0004154339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6020758,0.0707939,0.02169368,0.002480194,0.003649779,0.0005035299,0.0003362326,0.003151419,0.08873134,0.0001887577,0.004360347,0.202035],"study_design_scores_gemma":[0.4804502,0.4810029,0.02644879,0.00009471195,0.001055769,0.0007327048,0.00004700163,0.001152566,0.006110717,0.000122352,0.00275375,0.00002865977],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922469,0.004743643,0.000370898,0.0003329749,0.00005466563,0.0008479583,0.0005602907,0.00005149461,0.000791182],"genre_scores_gemma":[0.9921108,0.002516875,0.0009367784,0.0005669332,0.0001254019,0.001040466,0.001855131,0.00002224203,0.0008254082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002655257,"threshold_uncertainty_score":0.0140425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05774961993168776,"score_gpt":0.4387506707119048,"score_spread":0.3810010507802171,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}